SCHEMBL4183196

SCHEMBL4183196

CC(C)(C)OC(=O)NCC(=O)Cc1cccc(C=Cc2c(Cl)cccc2Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.38
GLS O94925 2/20 0.37
RAF1 P04049 1/20 0.37
POLB P06746 2/20 0.37
HPGD P15428 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
GLA P06280 1/20 0.37
CTSL P07711 1/20 0.36
DRD2 P14416 1/20 0.36
MAPK1 P28482 1/20 0.36
ATM Q13315 1/20 0.36
KDM4E B2RXH2 2/20 0.36
SYK P43405 1/20 0.35
NQO2 P16083 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4183191 1.00 NR1H4 (0.38) NR1H4GLSRAF1POLBHPGD
SCHEMBL4411726 0.83 POLB (0.45) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL4411730 0.83 POLB (0.45) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL4184524 0.81 CTSL (0.41) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL4184527 0.81 CTSL (0.41) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL8805143 0.81 NR1H4 (0.37) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL1294547 0.81 CTSL (0.52) GLSHPGDKMT2AMEN1CTSL
SCHEMBL1295524 0.79 POLB (0.49) GLSPOLBHPGDKMT2AMAPK1
SCHEMBL4178568 0.77 RAF1 (0.42) NR1H4RAF1POLBHPGDKMT2A
SCHEMBL4178572 0.77 RAF1 (0.42) NR1H4RAF1POLBHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10201545-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2019-02-12 US disclosed
US-9421210-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-08-23 US disclosed
US-20160193160-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2016-07-07 US disclosed
US-9314467-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2016-04-19 US disclosed
US-20150238497-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2015-08-27 US disclosed
US-20150166495-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2015-06-18 US disclosed
US-20150166494-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. 2015-06-18 US disclosed
US-8653142-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2014-02-18 US disclosed
US-20130253064-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. 2013-09-26 US disclosed
US-8420863-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ACUCELA, INC. (US) 2013-04-16 US disclosed
US-20120129860-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA, INC. (US) 2012-05-24 US disclosed
US-20090170841-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ACUCELA INC. (US) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166495-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20150166494-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20120129860-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20130253064-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20150238497-A1 STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20160193160-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-10201545-B2 Styrenyl derivative compounds for treating ophthalmic diseases and disorders ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885
US-20090170841-A1 Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders ALDH1A2, STARD3, TXNRD2 NR1H4 4001/4885GLS 3998/4885RAF1 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.